No Data
LIVZON PHARMA (01513.HK) spent 11.7541 million yuan to repurchase 0.3262 million A shares on January 22.
On January 22, Gelonghui reported that LIVZON PHARMA (01513.HK) announced the repurchase of 0.3262 million A shares at a cost of 11.7541 million yuan on January 22, 2025, with a repurchase price ranging from 35.9 to 36.21 yuan per share.
LIVZON PHARMA (01513.HK) spent 10 million yuan to repurchase 0.2764 million A-shares on January 21.
Gelonghui reported on January 21 that LIVZON PHARMA (01513.HK) announced that on January 21, 2025, it will spend 10 million yuan to repurchase 0.2764 million shares of A-shares, with a repurchase price per share ranging from 36.11 to 36.35 yuan.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
On January 20, LIVZON PHARMA (01513) spent approximately 9.9981 million yuan to repurchase 0.2749 million shares of A-shares.
LIVZON PHARMA (01513) announced that on January 20, 2025, it spent approximately 9.9981 million yuan to repurchase 27.4...
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet
